{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:49:06Z","timestamp":1778802546198,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunotherapy improves survival outcomes in cancer patients, but there is still an unmet clinical need in the treatment of brain metastases. Here, we used a mouse model to investigate the antitumor effect of programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) dual blockade on metastatic brain tumors and evaluated immune responses during treatment. After establishing hematogenous brain metastasis by transplanting murine bladder carcinoma MBT2 cells stably expressing secNLuc reporter via the internal carotid artery of C3H\/HeNCrl mice, we observed the formation of metastases not only in the brain parenchyma but also in the ventricles. The observed pathological areas showed that metastases in the ventricle were histologically larger than that in the brain parenchyma. Regarding the total tumor burden in the whole brain as revealed by Nluc activities, the combination of anti-PD-L1 antibody and anti-VEGF antibody showed a stronger anti-tumor effect than each single agent. Anti-PD-L1 antibody alone enhanced CD8<jats:sup>+<\/jats:sup> T cell priming in regional lymph nodes, increased the proportion of activated CD8<jats:sup>+<\/jats:sup> T cells in whole brain, and increased the density of CD8<jats:sup>+<\/jats:sup> cells in the brain parenchyma. Furthermore, anti-VEGF antibody alone decreased microvessel density (MVD) in ventricular metastases, and the combination treatment increased intratumoral CD8<jats:sup>+<\/jats:sup> cell density in the brain parenchyma and ventricular metastases. These results suggest that PD-L1 blockade enhanced cancer immunity not only in brain metastases lesions but also in the regional lymph nodes of the metastases, and that the addition of VEGF blockade increased the antitumor effect by increasing the infiltration of activated CD8<jats:sup>+<\/jats:sup> T cell and decreasing MVD.<\/jats:p>","DOI":"10.1007\/s10585-024-10309-y","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T03:41:08Z","timestamp":1725507668000},"page":"909-924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model"],"prefix":"10.1007","volume":"41","author":[{"given":"Chinami","family":"Masuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keigo","family":"Yorozu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsue","family":"Kurasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiko","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"10309_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0055-y","author":"AS Achrol","year":"2019","unstructured":"Achrol AS et al (2019) Brain metastases. Nat Rev Dis Primers 5(1):5","journal-title":"Nat Rev Dis Primers"},{"key":"10309_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-011-0203-y","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY (2012) Epidemiology of Brain Metastases. Curr Oncol Rep 14(1):48\u201354","journal-title":"Curr Oncol Rep"},{"issue":"24","key":"10309_CR3","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","volume":"18","author":"DS Chen","year":"2012","unstructured":"Chen DS, Irving BA, Hodi FS (2012) Molecular pathways: next-generation immunotherapy\u2013inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 18(24):6580\u20136587","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10309_CR4","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I et al (2023) The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56(10):2188\u20132205","journal-title":"Immunity"},{"key":"10309_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","volume":"86","author":"Y Yang","year":"2022","unstructured":"Yang Y, Cao Y (2022) The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol 86:251\u2013261","journal-title":"Semin Cancer Biol"},{"issue":"25","key":"10309_CR6","doi-asserted-by":"publisher","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","volume":"93","author":"F Yuan","year":"1996","unstructured":"Yuan F et al (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody. Proc Natl Acad Sci USA 93(25):14765\u201314770","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"10309_CR7","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-09-0731","volume":"15","author":"JP O\u2019Connor","year":"2009","unstructured":"O\u2019Connor JP et al (2009) Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 15(21):6674\u20136682","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10309_CR8","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2(10):1096\u20131103","journal-title":"Nat Med"},{"issue":"11","key":"10309_CR9","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"D Gabrilovich","year":"1998","unstructured":"Gabrilovich D et al (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92(11):4150\u20134166","journal-title":"Blood"},{"issue":"3","key":"10309_CR10","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","volume":"160","author":"T Oyama","year":"1998","unstructured":"Oyama T et al (1998) Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160(3):1224\u20131232","journal-title":"J Immunol"},{"issue":"1","key":"10309_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4049\/jimmunol.174.1.215","volume":"174","author":"MM Dikov","year":"2005","unstructured":"Dikov MM et al (2005) Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174(1):215\u2013222","journal-title":"J Immunol"},{"issue":"2","key":"10309_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","volume":"23","author":"N Horikawa","year":"2017","unstructured":"Horikawa N et al (2017) Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res 23(2):587\u2013599","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10309_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M et al (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73(2):539\u2013549","journal-title":"Cancer Res"},{"issue":"18","key":"10309_CR14","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","volume":"25","author":"OE Rahma","year":"2019","unstructured":"Rahma OE, Hodi FS (2019) The Intersection between tumor angiogenesis and immune suppression. Clin Cancer Res 25(18):5449\u20135457","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10309_CR15","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"24","key":"10309_CR16","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301","journal-title":"N Engl J Med"},{"key":"10309_CR17","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.3389\/fimmu.2018.03081","volume":"9","author":"M Georganaki","year":"2018","unstructured":"Georganaki M, van Hooren L, Dimberg A (2018) Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol 9:3081","journal-title":"Front Immunol"},{"issue":"9","key":"10309_CR18","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS et al (2020) Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med 52(9):1475\u20131485","journal-title":"Exp Mol Med"},{"issue":"11","key":"10309_CR19","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","volume":"18","author":"PS Steeg","year":"2021","unstructured":"Steeg PS (2021) The blood\u2013tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol 18(11):696\u2013714","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10309_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK (2020) The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases. Nat Rev Cancer 20(1):26\u201341","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10309_CR21","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1158\/2326-6066.CIR-21-0870","volume":"10","author":"C Alvarez-Breckenridge","year":"2022","unstructured":"Alvarez-Breckenridge C et al (2022) Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition. Cancer Immunol Res 10(8):996\u20131012","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10309_CR22","doi-asserted-by":"publisher","first-page":"100900","DOI":"10.1016\/j.xcrm.2022.100900","volume":"4","author":"\u00c1F \u00c1lvarez-Prado","year":"2023","unstructured":"\u00c1lvarez-Prado \u00c1F et al (2023) Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors. Cell Rep Med 4(1):100900","journal-title":"Cell Rep Med"},{"issue":"14","key":"10309_CR23","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.cell.2022.06.007","volume":"185","author":"J Biermann","year":"2022","unstructured":"Biermann J et al (2022) Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell 185(14):2591\u2013608.e30","journal-title":"Cell"},{"issue":"14","key":"10309_CR24","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","volume":"27","author":"I Smalley","year":"2021","unstructured":"Smalley I et al (2021) Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases. Clin Cancer Res 27(14):4109\u20134125","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10309_CR25","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.xcrm.2022.100620","volume":"3","author":"LJ Sudmeier","year":"2022","unstructured":"Sudmeier LJ, Hoang KB, Nduom EK, Wieland A, Neill SG, Schniederjan MJ, Ramalingam SS, Olson JJ, Ahmed R, Hudson WH (2022) Distinct phenotypic states and spatial distribution of CD8+ T cell clonotypes in human brain metastases. Cell Rep Med 3(5):100620","journal-title":"Cell Rep Med"},{"issue":"6","key":"10309_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s43018-023-00566-3","volume":"4","author":"V Wischnewski","year":"2023","unstructured":"Wischnewski V et al (2023) Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation. Nat Cancer 4(6):908\u2013924","journal-title":"Nat Cancer"},{"key":"10309_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbcan.2016.12.001","volume":"1","author":"FJ Lowery","year":"2017","unstructured":"Lowery FJ, Yu D (2017) Brain metastasis: unique challenges and open opportunities. Biochim Biophys Acta Rev Cancer 1:49\u201357","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"10309_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10585-019-10008-z","volume":"37","author":"C Masuda","year":"2020","unstructured":"Masuda C et al (2020) Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. Clin Exp Metastasis 37(1):199\u2013207","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"10309_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10585-021-10135-6","volume":"39","author":"C Masuda","year":"2022","unstructured":"Masuda C et al (2022) PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8(+) T cells in hematogenous metastasis model with lymphocyte infusion. Clin Exp Metastasis 39(2):335\u2013344","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"10309_CR30","first-page":"2918","volume":"37","author":"MS Soloway","year":"1977","unstructured":"Soloway MS (1977) Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37(2):2918\u20132929","journal-title":"Cancer Res"},{"issue":"3","key":"10309_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41422-020-0287-8","volume":"30","author":"X Hu","year":"2020","unstructured":"Hu X et al (2020) Meningeal lymphatic vessels regulate brain tumor drainage and immunity. Cell Res 30(3):229\u2013243","journal-title":"Cell Res"},{"issue":"2","key":"10309_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.immuni.2004.12.008","volume":"22","author":"T Calzascia","year":"2005","unstructured":"Calzascia T et al (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22(2):175\u2013184","journal-title":"Immunity"},{"issue":"5","key":"10309_CR33","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1158\/2159-8290.CD-21-0976","volume":"12","author":"MR Strickland","year":"2022","unstructured":"Strickland MR et al (2022) Tumor immune microenvironment of brain metastases: toward unlocking antitumor immunity. Cancer Discov 12(5):1199\u20131216","journal-title":"Cancer Discov"},{"issue":"7","key":"10309_CR34","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1084\/jem.20142290","volume":"212","author":"A Aspelund","year":"2015","unstructured":"Aspelund A et al (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212(7):991\u2013999","journal-title":"J Exp Med"},{"issue":"5","key":"10309_CR35","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0952-7915(98)80228-8","volume":"10","author":"DM Pardoll","year":"1998","unstructured":"Pardoll DM, Topalian SL (1998) The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10(5):588\u2013594","journal-title":"Curr Opin Immunol"},{"key":"10309_CR36","doi-asserted-by":"publisher","first-page":"101481","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano AE, Anandasabapathy N (2021) The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol 52:101481","journal-title":"Semin Immunol"},{"issue":"8","key":"10309_CR37","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","volume":"57","author":"T Osada","year":"2008","unstructured":"Osada T et al (2008) The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 57(8):1115\u20131124","journal-title":"Cancer Immunol Immunother"},{"key":"10309_CR38","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8247","author":"N Ishikura","year":"2022","unstructured":"Ishikura N et al (2022) Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors. Oncol Rep 47(2):36","journal-title":"Oncol Rep"},{"issue":"2","key":"10309_CR39","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.neuchi.2023.101412","volume":"69","author":"E Garrido","year":"2023","unstructured":"Garrido E et al (2023) Metastasis of the choroid plexuses: A systematic review of the literature and case illustration. Neurochirurgie 69(2):101412","journal-title":"Neurochirurgie"},{"issue":"1","key":"10309_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11060-009-9988-z","volume":"97","author":"A Della Puppa","year":"2010","unstructured":"Della Puppa A et al (2010) Solitary intra-ventricular brain metastasis from a breast carcinoma. J Neurooncol 97(1):123\u2013126","journal-title":"J Neurooncol"},{"issue":"6","key":"10309_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz GT et al (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20(6):607\u2013615","journal-title":"Nat Med"},{"issue":"2","key":"10309_CR42","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood.V88.2.667.bloodjournal882667","volume":"88","author":"AW Griffioen","year":"1996","unstructured":"Griffioen AW et al (1996) Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88(2):667\u2013673","journal-title":"Blood"},{"issue":"1","key":"10309_CR43","doi-asserted-by":"publisher","first-page":"13912","DOI":"10.1038\/s41598-021-93113-y","volume":"11","author":"T Iwai","year":"2021","unstructured":"Iwai T et al (2021) Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab. Sci Rep 11(1):13912","journal-title":"Sci Rep"},{"issue":"8","key":"10309_CR44","doi-asserted-by":"publisher","first-page":"e1466769","DOI":"10.1080\/2162402X.2018.1466769","volume":"7","author":"AL Hung","year":"2018","unstructured":"Hung AL et al (2018) TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology 7(8):e1466769","journal-title":"Oncoimmunology"},{"issue":"7","key":"10309_CR45","doi-asserted-by":"publisher","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","volume":"115","author":"D Taggart","year":"2018","unstructured":"Taggart D et al (2018) Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking. Proc Natl Acad Sci USA 115(7):E1540\u2013E1549","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10309_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","volume":"17","author":"N Nogami","year":"2022","unstructured":"Nogami N et al (2022) IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol 17(2):309\u2013323","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10309_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cllc.2022.07.016","volume":"23","author":"M Itchins","year":"2022","unstructured":"Itchins M et al (2022) A multi-center real-world experience of IMpower150 in oncogene driven tumors and CNS metastases. Clin Lung Cancer 23(8):702\u2013708","journal-title":"Clin Lung Cancer"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10309-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-024-10309-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10309-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T20:02:45Z","timestamp":1734984165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-024-10309-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10309"],"URL":"https:\/\/doi.org\/10.1007\/s10585-024-10309-y","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chinami Masuda, Shinichi Onishi, Keigo Yorozu, Mitsue Kurasawa, Mamiko Morinaga, Daiko Wakita, Masamichi Sugimoto are employees of Chugai Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals at Chugai Pharmaceutical Co. Ltd., and all animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at Chugai Pharmaceutical Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"This article does not contain any studies involving human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}